Novotech conducts multinational study for THVD-201 in Korea

Published: 2011-08-31 06:58:00

Updated: 2011-08-31 06:58:00

The U.S.-based TheraVida, Inc., a privately-held California biopharmaceutical company, has announced the start of a Phase 2 clinical trial of its lead product candidate THVD-201 for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI) in Korea, Australia and New Zealand, ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK